Startup
Apoglyx
Apoglyx is a pre-clinical stage company developing first-in-class Aquaporin-9 inhibitors with anti-inflammatory properties. Prioritized pipeline indications include solid tumors, intestinal perforation, and atopic dermatitis.
![](https://usercontent.one/wp/www.smileventurehub.com/wp-content/uploads/2021/10/Michael_3small-e1601569097171-180x180.jpg)
The company is based on the fundamental discovery of aquaporins by Nobel Laureate professor Peter Agre, Johns Hopkins University Medical School, and the extensive, collaborative scientific work with ApoGlyx founders Søren Nielsen, and Michael Rützler, at Århus University, Denmark and Per Kjellbom, Lund University, to establish that aquaporins are key pharmaceutical targets in life-threatening diseases.